Articoli con mandati relativi all'accesso pubblico - C KarapetisUlteriori informazioni
Non disponibili pubblicamente: 10
Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival
DH Murray, EL Symonds, GP Young, S Byrne, P Rabbitt, A Roy, ...
Journal of cancer research and clinical oncology 144, 1741-1750, 2018
Mandati: National Health and Medical Research Council, Australia
Current opinion on optimal treatment for colorectal cancer
TJ Price, E Segelov, M Burge, DG Haller, SP Ackland, NC Tebbutt, ...
Expert review of anticancer therapy 13 (5), 597-611, 2013
Mandati: UK Medical Research Council
Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing
K Chiam, GC Mayne, DI Watson, RJ Woodman, TF Bright, MZ Michael, ...
Annals of Surgical Oncology 25, 2731-2738, 2018
Mandati: National Health and Medical Research Council, Australia
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study
JK Coller, IA White, RM Logan, J Tuke, AM Richards, KR Mead, ...
Supportive Care in Cancer 23, 1233-1236, 2015
Mandati: National Health and Medical Research Council, Australia
Cetuximab alone or with irinotecan for resistant KRAS-, NRAS-, BRAF-and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomized phase II ICECREAM study
JD Shapiro, S Thavaneswaran, CR Underhill, KP Robledo, CS Karapetis, ...
Clinical colorectal cancer 17 (4), 313-319, 2018
Mandati: National Health and Medical Research Council, Australia
MRI rectal cancer in Australia and New Zealand: An audit from the PETACC‐6 trial
KL Gormly, C Coscia, T Wells, N Tebbutt, JA Harvey, K Wilson, ...
Journal of Medical Imaging and Radiation Oncology 60 (5), 607-615, 2016
Mandati: National Health and Medical Research Council, Australia
The association of health-care contact days with physical function and survival in CCTG/AGITG CO. 17
A Gupta, CJ O’Callaghan, L Zhu, DJ Jonker, RPW Wong, B Colwell, ...
JNCI: Journal of the National Cancer Institute 116 (8), 1313-1318, 2024
Mandati: Arnold Ventures LLC
Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites
Z Liu, JH Martin, W Liauw, SA McLachlan, E Link, A Matera, M Thompson, ...
European Journal of Clinical Pharmacology 78, 53-64, 2022
Mandati: National Health and Medical Research Council, Australia
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study
M Michael, W Liauw, SA McLachlan, E Link, A Matera, M Thompson, ...
Cancer Chemotherapy and Pharmacology 88, 39-52, 2021
Mandati: National Health and Medical Research Council, Australia
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial
J Tie, Y Wang, SN Lo, K Lahouel, JD Cohen, R Wong, JD Shapiro, ...
Nature Medicine, 1-10, 2025
Mandati: National Health and Medical Research Council, Australia
Disponibili pubblicamente: 50
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...
New England Journal of Medicine 377 (20), 1919-1929, 2017
Mandati: Cancer Research UK
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
New England Journal of Medicine 379 (24), 2342-2350, 2018
Mandati: US National Institutes of Health
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
Mandati: Research Foundation (Flanders)
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie, M Tacey, R Wong, ...
Annals of Oncology 26 (8), 1715-1722, 2015
Mandati: US National Institutes of Health
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study
JW Valle, D Palmer, R Jackson, T Cox, JP Neoptolemos, P Ghaneh, ...
Journal of clinical oncology 32 (6), 504-512, 2014
Mandati: Canadian Cancer Society, Cancer Research UK
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ...
The Lancet Oncology 21 (2), 261-270, 2020
Mandati: US National Institutes of Health, National Institute for Health Research, UK
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE …
HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ...
The Lancet Oncology 18 (9), 1159-1171, 2017
Mandati: Cancer Research UK, National Institute for Health Research, UK
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
J Tie, JD Cohen, Y Wang, L Li, M Christie, K Simons, H Elsaleh, ...
Gut 68 (4), 663-671, 2019
Mandati: US National Institutes of Health, Howard Hughes Medical Institute, National …
PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
CS Karapetis, D Jonker, M Daneshmand, JE Hanson, CJ O'Callaghan, ...
Clinical Cancer Research 20 (3), 744-753, 2014
Mandati: Canadian Cancer Society, Ontario Institute for Cancer Research
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
AK Nowak, WJ Lesterhuis, PS Kok, C Brown, BGM Hughes, DJ Karikios, ...
The Lancet Oncology 21 (9), 1213-1223, 2020
Mandati: National Health and Medical Research Council, Australia
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software